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Abstract 
Drug is single active chemical entity present in a medicine that is used for diagnosis, prevention and treatment of 
diseases. Adverse drug reaction is unexpected effect of drug on animal and human being and considered as one 
of causes of morbidity and mortality of hospitalized patients. Although many drug reactions are preventable such 
as those associated with prescription errors while others are not preventable. The adverse drug reactions are often 
not discovered until after the drug has been marketed. The occurrence of ADR can be explain on basis of the 
drug’s pharmacology and show apparent dose-response relationship in susceptible animal and human being. 
Adverse drug reactions caused by immune and non-immune mechanisms are a major cause of morbidity and 
mortality worldwide. They are the most common iatrogenic illness, complicating 5% to 15% of therapeutic drug 
courses. Adverse drug reactions can be divided schematically into two major categories: type A and type B. 
Type A reactions are common, predictable and may occur in any individual. Type B ADRs are uncommon and 
unpredictable and only occur in susceptible individuals. A critical factor in the drug response such as in ADRs 
could be the inter-patient differences in plasma concentrations arising from the same drug regimen. 
Pharmacogenomics is likely to be particularly useful for drugs that have variable kinetics and dynamics, and 
narrow therapeutic index. Management strategies employed for the ADRs is categorized as drug withdrawal, 
dose reduction, additional treatment for ADR, and no change in regimen with no additional treatment. Managing 
these cases should be done immediately after their appearance and those individuals or animals with the problem 
should be carefully handled with the appropriate medical expertise. Better approaches must be devised for 
reporting and assessing ADR. In addition, pharmaceutical companies should strive to reduce the adverse effect 
of a drug. 
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INTRODUCTION 
Drug is single active chemical entity present in a medicine that is use for diagnosis, prevention and treatment of 
diseases.  (Mererjone, 2003). The person-to-person variability of drug response is a major problem in clinical 
practice and drug development (Meyer, 2000). It can lead to therapeutic failure or adverse effects of drugs 
(ADRs) in individuals or subpopulations of patients. Adverse drug reaction is unexpected effect of drug on 
animal and human being and considered as one of causes of morbidity and mortality of hospitalized patients 
(Ditto, 2004).  
A productive hospital-based reporting program can be instrumental in providing valuable information 
regarding potential problems of drug usage in an institution. Through these efforts, problems are identified and 
resolved, which results in continuous improvement inpatient Care (Murphy and Frigo, 1993). Spontaneous 
reporting program, a common method of drug surveillance is capable of recognizing ADRs in the daily medical 
practice even though under reporting and absence of information on number of people actually exposed to the 
drug are its disadvantages (Alvarez-Requejo et al., 1998).  
Although many drug reactions are preventable such as those associated with prescription errors while 
others are not preventable. The adverse drug reactions are often not discovered until after the drug has been 
marketed. Pharmaceutical companies strive to work out the adverse effect profile of a drug before it is marketed, 
but because the complete range of adverse effects is not known, therefore, most severe drug induced reactions 
cannot be elucidated before licensing, therefore efficient post marketing surveillance is needed. However, even if 
improved surveillance is carried out the problem will not be resolved. As more drugs are marketed and as more 
individuals take multiple drugs, the occurrence of adverse drug reactions will probably continue to increase. 
Adverse drug reaction are still considered as  problem of drug therapy in association with considerable 
morbidity,  mortality, decrease compliance and therapeutic success as well as high direct  and indirect medical 
cost (Tripathis,2003). There for the objectives of this seminar paper are: to high light   the causality, clinical   
manifestation and management of ADR, and to recommend further study in the area of ADR. 
 
DEFINITION AND EPIDEMOLOGY  
Definition  
Adverse drug reaction can be defined as any noxious unintended and undesired effects of a drug that occur at 
doses used for prevention, diagnosis or treatment or  it  is an unwanted or harmful reaction following the 
administration of a medication or combination of medications which  is suspected to be related to the medication. 
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The reaction may be a known side effect of the drug or it may be a new previously unrecognized ADR. (Jill et al., 
2008). 
 
Epidemiology  
Adverse drug reactions caused by immune and no immune mechanisms are a major cause of morbidity and 
mortality worldwide. They are the most common iatrogenic illness, complicating 5% to 15% of therapeutic drug 
courses. In the United States, more than 100,000 deaths are attributed annually to serious adverse drug reactions. 
Three percent to six percent of all hospital admissions are because of adverse drug reactions and 6% to 15 % of 
hospitalized patients (2.2 million persons in the United States in 1994) experience a serious adverse drug 
reaction .Epidemiologic data support the existence of specific factors that increase the risk of general adverse 
drug reactions, such as female, gender, or infection with human immunodeficiency virus (HIV), or 
herpes( Alvarez-Requejo et al.,1998) Factors associated with an increased risk for hypersensitivity drug 
reactions include asthma, systemic lupus erythematosus, or use of beta blockers although atopic patients do not 
have a higher rate of sensitization to drugs, they are at increased risk for serious allergic reactions .Incidence and 
severity of ADRs vary by patient characteristics (e.g., age, sex, coexisting disorders, genetic or geographic 
factors) and by drug factors (e.g., type of drug, administration route, treatment duration, dosage, bioavailability). 
Incidence is probably higher and is more severe among the elderly. The contribution of prescribing and 
adherence errors to the incidence of ADR is unclear (Lazarou et al., 1998) 
In animal recent UK study following vaccination of dog revealed  a similarly  incidence of sign of 
health in recently  vaccinated and unvaccinated dog s which account 19% and 25%  into week period (Jill et 
al.,2008). 
 
CAUSALITIES OF ADVERSE DRUG REACTION 
In assessing the likelihood of ADR, a causality rating is assigned to each drug using the validate Kramer’s 
algorithm using the parameter like: previous experience of ADR, no other factor related to underlying disease, as 
well as no other drug-unrelated etiology may explain the presence of the clinical manifestation in the patient and 
time elapsed between drug administration and its manifestation; its onset also immediately follows drug 
administration (Kramer et al., 1979). ADR attenuates after drug reduction or disappears after drug interruption. 
Its reappearance after drug re-administration; not done in any of the patients are analyzed (Hutchinson et al., 
1979). The diagnostic criteria in Kramer’s algorithm are divided into six axes, with a scoring system 
incorporated into each axis. The cumulative score corresponds to the probability that the clinical manifestation 
represents an ADR and compared to the score obtained for a suspected ADR caused by a drug interaction with 
the scores obtained for the clinical manifestation caused by the single drugs (table 1 below). When a candidate 
single drug had a higher score, that drug rather than the interaction is held responsible for the ADR. The four 
distinct defined classes with regard to ADRs causality are:  
 Certain: temporal or spatial correlation confirmed by de challenge and re challenge and/or laboratory test  
 Probable: temporal or spatial correlation confirmed by de challenge and not induced by disease, and/or 
recovery on withdrawal of the drug if no other drug was withdrawn and no therapy given; 
 Possible: a possible alternative explanation exists when a strict temporal relationship is not clear, and/or a 
recovery occurs after therapy prescription in addition to drug withdrawal, and/or more than one drug is 
suspected 
 Unclear causality: the clinical event could be consistently attributed to either the underlying disease or to 
drug –related cause. 
 
Table .1: Six axis and total score in Kramer’s algorithm of ADR    
Axis  Scoring of evidence of reaction  
 Favors  Uncertain  Against  
History  +1 0 -1 
No alternative illness  +2 0 -1 
Timing event  +1 0 -2 
Drug level  +1 0 -1 
Dechallege  +1 0 -1 
Rechallege  +1 0 -1 
Total score  +7 0 -7 
Source: (Hutchinson, et al. 1979) 
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CLASSIFICATION OF ADVERSE DRUG REACTION 
Immunologic and Non-immunologic Drug Reactions 
Drug reactions can be classified into immunologic and non immunologic etiology (table.2). The majority (75% 
to 80%) of adverse drug reactions are caused by predictable, no immunologic effects. The remaining 20% to 
25 % of adverse drug events are caused by unpredictable effects that may or may not be immune mediated. 
Immune-mediated reactions account for 5% to 10% of all drug reactions and constitute true drug hypersensitivity, 
with IgE-mediated drug allergies falling into this category (Marc et al., 2003). 
 
Table 2: Immunologic and Non-immunologic Drug Reactions  
Type Example 
Immunologic  
• Type I reaction (IgE-mediated)  
 
• Type II reaction (cytotoxic)  
• Type III reaction (immune complex)  
• Type IV reaction (delayed, cell-mediated) 
Specific T-cell activation  
• Fas/Fas ligand-induced apoptosis 
• Other 
 
 Anaphylaxis from β-lactam antibiotic Hemolytic anemia 
from penicillin  
 Serum sickness from anti-thymocyte globulin Contact 
dermatitis from topical antihistamine 
 Morbilliform rash from sulfonamides 
 Stevens-Johnson syndrome  
 Toxic epidermal necrolysis  
 Drug-induced, lupus-like syndrome 
 Anticonvulsant hypersensitivity syndrome  
Non-immunologic 
Predictable  
• Pharmacologic side effect  
• Secondary pharmacologic side effect 
• Drug toxicity  
• Drug-drug interactions  
• Drug overdose  
 
Unpredictable  
• Pseudo allergic  
• Idiosyncratic  
• Intolerance 
 
 
 Dry mouth from antihistamines  
 Thrush while taking antibiotics 
 Hepatotoxicity from methotrexate  
 Seizure from theophylline while taking erythromycin 
Seizure from excessive Lidocaine (Xylocaine)  
 
 Anaphylactic reaction after radio contrast media 
 Hemolytic anemia in a patient with G6PD* deficiency after 
primaquine therapy  
 Tinnitus after a single, small dose of aspirin 
*G6PD = glucose-6-phosphate dehydrogenate 
 Source: (Marc et al., 2003) 
  
Type A and B drug reaction 
Adverse drug reactions can be divided schematically into two major categories: type A and type B. Type A 
reactions are common, predictable and may occur in any individual. Type B ADRs are uncommon and 
unpredictable and only occur in susceptible individuals (Pirmohamed et al., 2001). Type A reactions are the most 
frequent and can be observed in as many as 25–45% of patients. These represent an exaggeration of the known 
primary and/or secondary pharmacological actions of the drug, they are dose related and could probably be 
avoided and/or foreseen (Carbonin et al., 1991). In contrast, type B reactions or idiosyncratic drug reactions 
cannot be explained on the basis of the drug’s pharmacology and show no apparent dose–response relationship 
in susceptible individuals. They are often undiscovered until the drug has been marketed and are generally 
associated with high mortality. Genetically determined alterations in drug metabolizing enzymes can predispose 
to both pharmacological and idiosyncratic toxicity. Single gene defects account for only a minority of ADRs. For 
most adverse reactions, particularly of an idiosyncratic nature, predisposition seems to be multifactorial, 
involving not only defects at multiple gene loci but also environmental factors such as concomitant infections 
(Hallas et al., 1990). 
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Table 3 .Characteristics of Type A and Type B adverse drug reactions  
Characteristics Type A Type B 
Dose dependency Usually shows a good relationship No simple relationship 
Predictable from known 
pharmacology 
Yes Not usually 
 
Host factors Genetic factors might be important  Dependent on host  factors 
Frequency Common Uncommon 
Severity Variable but usually mild Variable proportionately severe 
Clinical burden High morbidity and low mortality High morbidity and mortality 
Overall proportion of 
adverse drug reactions 
80% 20% 
First detection Phases I–III Usually phase IV 
Animal models Usually reproducible in animals No known animal models  
Source: (Giovanni et al., 2003) 
 
GENETIC POLYMORPHISM AFFECTING ADVERSE DRUG REACTION 
Genetic polymorphism and drug kinetics 
CYP and ABC genes 
Most work has focused on enzyme polymorphism in drug oxidation and conjugation as risk factors for drug 
toxicity but genes involved in cell repair mechanisms, elaboration of cytokines and immune responsiveness 
cannot be excluded to predict individual susceptibility to different forms of ADRs (Hutchinson et al., 1979). 
Genetic polymorphisms are a source of variation of drug response in the human body. In relation to ADRs, most 
in tersest has centered on the involvement of pharmacokinetic factors and, in particular, drug metabolism. 
However, there is now increasing realization that genetic variation in drug targets (pharmacodynamic factors) 
might also predispose to ADRs, although research into this area is in its infancy ( Alvarado et al.,2002). 
A critical factor in the drug response such as in ADRs could be the inter-patient differences in plasma 
concentrations arising from the same drug regimen. Many drugs are substrates for cytochrome P450 (CYP) 
enzyme is forms and of Adenosine Tri phosphate binding cassette (ABC) membrane transporter proteins. Several 
polymorphisms that effect CYP genes and ABC genes have been described to alter the protein product function 
influencing metabolism, absorption, distribution and excretion of many drugs and to contribute to many 
clinically relevant diseases (Evans et al. 1999). 
 
CYP genes 
There are more than 30 families of CYP genes in humans and all of them have genetic variants, many of which 
translate into functional changes in the proteins encoded (Nebert et al.,2002). 
One member of this family, CYP2D6 gene, represents one of the most studied and best understood 
examples of pharmacogenetic variation in drug metabolism that is responsible for the metabolism of more than 
100 drugs including many central nervous system and cardiovascular drugs (Hosking et al.,2002).More than 75 
CYP2D6 alleles have now been described .Using so called “probe drugs” like de brisoquine or sparteine, 
CYP2D6 polymorphisms can be subdivided in poor, normal, rapid and ultra rapid  metabolism activity forms. 
Thus, in multi-drug therapies drug–drug interactions can cause ADRs or less therapeutic efficacy (Evans et al., 
2003). 
 
ABC genes 
The ABC genes represent the largest family of Tran’s membrane proteins described in human genome the 
principal function of ABC proteins is to translocate a variety of substrates across extra and intra-cellular 
membrane including several anticancer drugs, cardiac glycoside (digoxine), immunosuppressive agents, 
glucocorticoids and many other medications including some antiretroviral drugs. In the intestine ABC proteins 
limit drug entry into the body. Particular ABC proteins are also present in the apical membrane of many other 
epithelial barriers such as the blood brain, blood testis, and maternal-fetal barrier. A member ABC family is the 
ABCB1 gene. Synonymous single-nucleotide polymorphism (3435C→T) (single-nucleotide polymorphism that 
does not alter the amino acid encoded) in the axon 26 of the ABCB1 gene has been associated with variable 
expression of transporter protein in the duodenum. In patients with ABCB1 3435-TT genotype, duodenal 
expression of the gene was less than half respect to patients with the ABC1 3435-CC genotype. Dioxin shows 
higher bio availability in subjects with the ABCB1 3435-TT genotype. Interestingly, most substrate of 
transporter protein is also metabolized by the CYP3A4 enzyme. This is of particular importance because 
transporter protein and CYP3A4 enzyme are localized in tissue with major function for drug disposition, such as 
small intestine and liver (Schwab et al., 2003). Generally speaking there is not a clear relationship between 
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MDR1 3435C→T polymorphism, transporter protein expression and plasma concentrations of substrates. This 
could be due to the following confounding factors: 
• The effect of the transporter protein expression polymorphism on protein tissue level expression is 
rather modest, 
• Disposition of most transporter protein substrates is also determined by other  factors, such as 
metabolism (e.g. CYP3A4) or active transport by other ABC proteins transporters,  
• Modifications of drug disposition may occur by exogenous factors (e.g. diet, drugs), which could 
explain different results, even if the same drug is investigated, 
• The presence of multiple SNPs in the transporter protein gene and pronounced inter-ethnic differences 
in frequencies of some of these polymorphisms, 
• Not all pharmacokinetic parameters are likely to be determined to a major extent by modulation of 
intestinal transporter protein expression (Schwab, 2003). 
 
Genetic polymorphism and drug toxicity 
Pharmacogenomics is likely to be particularly useful for drugs that have variable kinetics and dynamics, and 
narrow therapeutic index.  For example the three classes of anti-HIV drugs currently used, nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease 
inhibitors (PIs), certainly fit in this category. Adverse effects caused by this class of drugs can be divided into 
several categories. Recently considerable interest has been focused on the hypersensitivity reactions caused by 
abacavir (at least 5% of patients treated) and on the predictive potential role of pharmacogenomics ( Mallal  et 
al.,2002) .The followings are  some  of adverse reaction  of  drugs ; 
 
Dose related effects 
There are marked inter-patient differences in plasma concentrations arising from the same drug regimen. For 
those adverse reactions where a clear dose–response relationship can be demonstrated, it can be hypothesized 
that patients who have low expression or deficiency of a particular metabolizing enzyme will be achieve  high  
plasma drug concentrations and enhanced toxicity(Fellay et al., 2002).   
This has been clearly shown with non-HIV drugs and with HIV antiretroviral drugs. For example, drug 
crystallization in urine and formation of renal stones is a well-known adverse effect associated with high plasma 
concentrations. Although environmental factors such as hot climate are also important the role of CYP 
polymorphism seems to be dramatic. A good relationship has also been shown between ritonavir and 
neurological and gastro-intestinal ADRs. Ritonavir is the most potent inhibitor of the CYP3A4 enzyme system 
and the combination of ritonavir and indinavir causes inhibition of the CYP3A4 increasing drug plasma 
concentrations (Lemberg et al., 2002). Both drugs are also targeted by the transporter protein that may be 
important in determining plasma concentrations. A similar situation exists in the case of efavirenz, the newest 
NNRTi which is poorly absorbed into CFS, where high plasma levels predict CNS side effects (Pirmohamed, et 
al., 2001). Efavirenz is metabolized by CYP3A4 to inactive hydrolyte metabolites which undergo glucuronide 
conjugation and are subsequently eliminated by the kidneys (Dean et al., 2001).  
 
Mitochondrial toxicity 
Nucleoside analogues that inhibit the HIV reverse transcriptase can also inhibit the human DNA polymerase. 
Depletion in mitochondrial DNA and consequent mitochondrial toxicity is at least partially responsible for 
ADRs such as lactic acidosis, hepatic steatosis, myopathy, cardiomyopathy, peripheral neuropathy, pancreatitis, 
and possibly the Lipodystrophy syndrome (LD) (Carr and Cooper, 2000). The gold standard for the diagnosis of 
nucleoside-related mitochondrial toxic effects is muscle or liver biopsy. However, biopsy is not practical for 
routine screening and monitoring. Random measurements of venous lactate have been used to monitor for 
mitochondrial damage, but the clinical usefulness of this method remains unclear. Lack of specificity is a 
problem, as is technical and physiological variability. In a recent study changes in mitochondrial DNA relative to 
nuclear DNA (cytochrome-c oxidase subunit-I gene, CCOI and polymerase accessory subunit gene, ASPOLG, 
respectively) in the peripheral blood cells is quantified by real-time polymerase chain reaction. (Coté et al., 
2002).  
 
Lipodystrophy syndrome 
Lipodystrophy constitute a group of rare disorders characterized by highly variable or absence of adipose tissue. 
They may be inherited or acquired and are accompanied by insulin resistance, diabetes and hyperlipidaemia, and 
associated vascular disease. (Shevitz et al., 2001) The syndrome is reported to occur after the use of Ortiz and 
PIs. One hypothesis suggests it may be due to the inhibition of lipid and adipocyte regulatory proteins that have 
partial homology to the catalytic site of HIV-1 protease. Some features of this syndrome have been suggested to 
represent the mitochondrial toxicity of NRTIs. Thus, dissection of genetic predisposition is going to be difficult 
Journal of Medicine, Physiology and Biophysics                                                                                                                              www.iiste.org 
ISSN 2422-8427     An International Peer-reviewed Journal 
Vol.23, 2016 
 
12 
and indeed is probably the result of a complex interaction between the disease, drugs, as well as host (Hogan et 
al., 2001).  
The genetic factor TNF can be considered  to involved in the predisposition to lipodystrophy syndrome, 
but the same locus and more in general the MHC are suspected to play an important role in several immune 
mediated ADRs. A possible candidate gene in predisposing LD is the Tumor Necrosis Factor-gene (TNF). The 
TNF- locus is located within the MHC in the class III region. The TNF- is a candidate gene because it is thought 
to play a role in the insulin-resistance adipose tissue metabolism and viability and glucose homeostasis 
(Pirmohamed et al., 2001). Association between lipodystrophy and Tumor Necrosis Factor- gene has recently 
been investigated using a case-control design. Individuals are genotyped for the −238 and −308 G→A transition 
functionally active polymorphisms in the promoter region of TNF and the results suggests the frequency of the 
allele 238A was significantly more represented in the HIV-positive patients with lipodystrophy than HIV-
negative controls without lipodystrophy. Thus the TNF 238A allele can be considered as a susceptibility factor 
which is neither sufficient for nor absolutely necessary to the induction of Lipodystrophy (Maher et al., 2002). 
 
Hypersensitivity 
True hypersensitivity adverse drug reactions are great imitators of disease and may present with involvement of 
any organ system with or without fever, and may also involve one or more internal organs. Drug reactions 
commonly manifest with dermatologic symptoms caused by the metabolic and immunologic morbidly form 
rashes activity of the skin. The most common dermatologic manifestation of drug reaction is typically, an 
erythematous, maculopapular rash appears within one to three weeks after drug exposure, originates on the trunk, 
and eventually spreads to the limbs. Urticaria is typically a manifestation of a truly allergic, Type I reaction, but 
it may appear with Type III or pseudo allergic reactions as well. Severe non allergic, hypersensitivity cutaneous 
reactions (i.e., erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis) represent 
bulbous skin diseases that require prompt recognition because of their association with significant morbidity and 
mortality. Eczematous rashes are most commonly associated with topical medications and usually represent 
contact dermatitis, which is classified as Type IV reaction to a drug exposure (Pirmohamed et al., 2002).  
Drug hypersensitivity is about 100 times more common in HIV-1 patients than in general population 
and it complicates 3–20% of all pharmaceutical prescriptions. Nevirapine, delaviridine and efavirenz (NNRTIs), 
acacavir (NRTI) and amprenavir (PI) are the common antiretroviral drugs that may cause hypersensitivity. 
Particular interest has been focused on the hypersensitivity to abacavir. Despite the fact that this event occurs at 
an incidence of <5%, its severity and lethality (2–4 per 100,000 patients treated), even following an aggressive 
treatment, warrant careful evaluation of the patient for whom abacavir has to be prescribed (Clay, 2002). Several 
observations support the possibility that genetic susceptibility factors for this syndrome involve genetic loci 
situated within the MHC region. The susceptibility locus or loci marked by the presence of different loci, could 
easily participate directly in recognition of the abacavir-specific antigen by the immune system.  
The gene loci of TNF are approximately 200KB apart, not in strict linkage disequilibrium, but certainly 
close enough to exhibit considerable overlapping in the same set of abacavir hypersensitive patients. Available 
data suggest that the detection of the specific region involved in abacavir hypersensitivity does not need to be 
based solely on strictly defined blocks of linkage disequilibrium (Rose, 2002) Of course; the existence of 
different mechanisms or many genetic factors is commensurate with the predicted heterogeneity of complex 
traits and pharmacogenetic mechanism and should not come as a surprise. Although the arbitrary candidate-
gene-variation panel described cannot be used for definitive conclusion in terms of applicability for screening 
test for hypersensitivity reaction to abacavir, it is possible that additional genetic markers with sufficient 
predictive values involving racially diverse populations provide a plausible basis for the development of 
sufficient predictive test as well as for an increased understanding of the pathogenesis of this potentially life-
threatening ADRs (Lindpainter, 2002). 
 
MANAGEMENT OF ADVERSE DRUG REACTION 
Management strategies employed for the ADRs is categorized as drug withdrawal, dose reduction, additional 
treatment for ADR, and no change in regimen with no additional treatment. Further, categorization of the 
outcome of ADRs is done for response after de challenge and re challenge as well as the final outcome of the 
event (Jimmy et al., 2006).  
For dose-related ADRs, modifying the dose or eliminating or reducing precipitating factors may suffice. 
Increasing the rate of drug elimination is rarely necessary. For allergic and idiosyncratic ADRs, the drug usually 
should be withdrawn and not tried again. Switching to a different drug class is often required for allergic ADRs 
and sometimes required for dose-related ADRs. The most important and effective therapeutic measure in 
managing drug hypersensitivity reactions is the discontinuation of the offending medication, if possible. 
Alternative medications with unrelated chemical structures should be substituted when available (Busto et al., 
1982).  
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The clinical consequences of medication cessation or substitution should be closely monitored. In the 
majority of patients, symptoms will resolve within two weeks if the diagnosis of drug hypersensitivity is correct. 
Additional therapy for drug hypersensitivity reactions is largely supportive and symptomatic. Systemic 
corticosteroids may speed recovery in severe cases of drug hypersensitivity. Topical corticosteroids and oral 
antihistamines may improve dermatologic symptoms. The severe drug reactions of Stevens-Johnson syndrome 
and toxic epidermal necrolysis require additional intensive therapy. Thus the following points are considered to 
prevent ADR (Tripathi, 2003); 
• Avoid all inappropriate use of drug in context of patient’s clinical condition. 
• Use of appropriate dose, route and frequency of administration on base of patients, specific variable. 
• Elicit and take into consideration previous history of drug reaction. 
• Elicit history allergic disease exercise caution  
• Rule out possibility drug interaction when more than one drug is prescribed. 
• Adopt correct drug  administration technique  
• Carry out appropriate laboratory monitoring.   
 
CONCLUSION AND RECOMMENDATIONS 
Adverse drug reaction is one of causes of morbidity and mortality on animal as well as human being. Sex, gender 
and immune suppression increases the risk of ADR. The occurrence of ADR can be explain on basis of the 
drug’s pharmacology and show apparent dose-response relationship in susceptible animal and human being. 
Pharmaceutical companies strive to work out the adverse effect profile of a drug before it is marketed, because 
the complete range of adverse effects is not known, therefore efficient post marketing surveillance is needed. 
Although, improved surveillance is carried out the problem will not be resolved. Managing this cases should be 
done immediately after their appearance and those individuals or animals with the problem should be carefully 
handled with the appropriate medical expertise. 
In line with the above conclusive statements the followings are some of the recommendations:   
 Better approaches must be devised for reporting and assessing ADR. 
 Medical and veterinary professionals should be trained in diagnosing and managing ADR. 
 Pharmaceutical companies should strive to reduce the adverse effect of a drug. 
 Further research should be conducted in the area of ADR.  
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